Business
Lexaria's DehydraTECH-CBD Achieves Superior Human Blood Absorption Levels
KELOWNA, BC / ACCESSWIRE / December 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug
About this update from Lexaria Bioscience Corp.
[{"type":"text","content":"KELOWNA, BC / ACCESSWIRE / December 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the \"Company\" or \"Lexaria\"), a global innovator in drug delivery platforms is pleased to announce it has demonstrated superior cannabidiol (\"CBD\") blood absorption levels from its patented DehydraTECH-CBD™ relative to those of published, pharmaceutical-grade CBD industry comparators in its recently completed, multi-week human clinical hypertension study HYPER-H21-4.In a 2017 randomized clinical trial that evaluated a non-Lexaria, pharmaceutical-grade, plant-derived CBD formulation published by Devinski et. al., an average blood plasma CBD level of 23.0 ng/mL was evidenced after 22 days (so-called, \"steady state\"1) of daily dosing at a 5 mg/kg CBD dose level. By comparison, in Lexaria's 2022 HYPER-H21-4 hypertension study, a 45.8% higher average blood plasma level (33.3 mg/mL) was reached at DehydraTECH-CBD's lowest dose level tested of just 3.38 mg/kg, climbing to a blood plasma level that was 133.4% higher (53.7 ng/mL) at its highest dose level tested of 4.46 mg/kg.The Devinsky publication also examined higher CBD dosing at a level of 10 mg/kg, evidencing a blood level of 62.1 ng/mL. Although Lexaria's HYPER-H12-4 study did not see the need to dose as high as 10 mg/kg, the data trend observed at its 3.38 and 4.46 mg/kg dose levels extrapolated linearly to 10 mg/kg would be expected to reach a level of 149.5 ng/mL; a 141% improvement over the Devinsky CBD formulation.Similarly, a 2019 study published by Wheless et. al., also evaluated average CBD levels in blood following dosing to steady-state1 over a multi-day period, using a different pharmaceutical-grade, synthetic CBD formulation. At a 10 mg/kg dose level in the Wheless study, the non-Lexaria synthetic CBD reached a level within blood plasma of 91 ng/mL.; DehydraTECH-CBD absorption outperformed this synthetic CBD by 64% improvement upon linear extrapolation.\"DehydraTECH-CBD has repeatedly shown that it can be administered at much lower dose levels than other CBD formulations to achieve effective levels within the blood stream, as supported by this pharmaceutical-industry peer comparison,\" said Chris Bunka, CEO of Lexaria Bioscience Corp. \"This is extremely important to patients hoping to achieve positive health outcomes while using lower levels of medication with ...